AZD 5069

Drug Profile

AZD 5069

Alternative Names: AZD5069

Latest Information Update: 08 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; MedImmune
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coronary disorders; Head and neck cancer; Solid tumours
  • Phase I/II Pancreatic cancer
  • Discontinued Asthma; Bronchiectasis; Chronic obstructive pulmonary disease

Most Recent Events

  • 08 Aug 2018 AstraZeneca completes a phase Ib/II trial in Pancreatic cancer (Combination therapy, Metastatic disease) in United Kingdom and USA (PO) (NCT02583477)
  • 24 Jun 2018 Biomarkers information updated
  • 31 Dec 2017 AstraZeneca and King College London complete a phase II trial in Coronary disorders in United Kingdom (EudraCT2016-000775-24) (ISRCTN48328178)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top